Skip to content

Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis

Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis- An Open Label randomized Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181205001
Enrollment
Unknown
Registered
2018-12-05
Start date
2018-11-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis PsA

Interventions

Will be put on Tofacitinib 5 mg twice daily,Will be put on Methotrexate weekly in increasing dose with maximum dose of 25 mg weekly
Experimental Drug,Active Comparator Drug
Tofacitinib 5 mg BD,Methotrexate 25 mg weekly

Sponsors

Globe Pharmaceuticals Limited
Lead Sponsor
Department of Rgheumatology&#44
Collaborator
Bangabandhu Sheikh Mujib Medical University
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Male or female patients more than 18 years Psoriatic arthritis > 3 months with peripheral involvement diagnosed on the basis of CASPAR criteria Unresponsive to more than 2 NSAIDs at maximum recommended doses for more than 4 weeks, i.e 2 weeks for each NASID Patients with active disease PsA with or without extra-articular features like enthesitis, dactylitis and nail changes

Exclusion criteria

Exclusion criteria: Systemic infections requiring hospital admission during the past 6 months A history of active infectious disorders (including active or latent tuberculosis), and/or a history of chronic or recurrent serious infective diseases, opportunistic infections Hemoglobin (Hb) upper limit of normal reference range GFR less than 50 mL/min Alanine aminotransaminase (ALT) more than 2 times of ULN Pregnant or breast feeding, females of child-bearing potential not using highly effective contraception New York Heart Association Class III and IV congestive heart failure Evidence or history of malignancy, with the exception of adequately treated or excised non-metastatic basal or squamous cell cancer of the skin or cervical carcinoma in situ Any lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease

Design outcomes

Primary

MeasureTime frame
ACR-20 response at 1, 3 and 6 months Yes/no

Secondary

MeasureTime frame
ASDAS-CRP at 1, 3 and 6 months Numerical,DAPSA at 1, 3 and 6 months Numerical,DAS 28- ESR at 1, 3 and 6 months Numerical,HAQ-DI at 1, 3 and 6 months Numerical,PASI score at 1, 3 and 6 months Numerical,MASES at 1, 3 and 6 months Numerical

Countries

Bangladesh

Contacts

Public ContactPrayush Sharma

Bangabandhu Sheikh Mujib Medical University

drprayush@gmail.com+8801535157897

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026